Literature DB >> 20462833

Mechanisms of resistance to hormonal treatment in breast cancer.

P Eroles1, A Bosch, B Bermejo, A Lluch.   

Abstract

Endocrine therapy is a cornerstone in hormone-dependent breast cancer treatment. Despite the effectiveness of this type of treatment, a significant percentage of tumours develop resistance, and hence, patients relapse. This raises the question of which mechanisms are activated by hormone-dependent tumours to become resistant to antihormonal therapy. The aim of this review is to summarise the current knowledge on structure and mechanisms of action of oestrogen receptors and the possible mechanisms of resistance known to date, focusing on the existing crosstalk between oestrogen receptor and growth factor receptor pathways as well as the influence of drug metabolism in its effectiveness. Finally, the clinical evidence of hormonal therapy resistance and the future directions for optimising breast cancer treatment is also discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462833     DOI: 10.1007/s12094-010-0500-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  60 in total

Review 1.  Estrogen receptor beta--a new dimension in estrogen mechanism of action.

Authors:  J A Gustafsson
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

Review 2.  Similarities and distinctions in the mode of action of different classes of antioestrogens.

Authors:  A E Wakeling
Journal:  Endocr Relat Cancer       Date:  2000-03       Impact factor: 5.678

Review 3.  Diversity in the mechanisms of gene regulation by estrogen receptors.

Authors:  Rocio Sanchez; Denis Nguyen; Walter Rocha; John H White; Sylvie Mader
Journal:  Bioessays       Date:  2002-03       Impact factor: 4.345

4.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors:  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2006-07       Impact factor: 6.875

5.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

Authors:  T A Jackson; J K Richer; D L Bain; G S Takimoto; L Tung; K B Horwitz
Journal:  Mol Endocrinol       Date:  1997-06

6.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

7.  AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

Authors:  Wenhui Zhao; Qingyuan Zhang; Xinmei Kang; Shi Jin; Changjie Lou
Journal:  Biochem Biophys Res Commun       Date:  2009-01-29       Impact factor: 3.575

8.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

9.  Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors:  Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal:  Nature       Date:  2008-11-12       Impact factor: 49.962

10.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Authors:  Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren
Journal:  Breast Cancer Res       Date:  2005-01-28       Impact factor: 6.466

View more
  4 in total

Review 1.  How can grafted breast cancer models be optimized?

Authors:  Séverine Mollard; Yoanne Mousseau; Yasser Baaj; Laurence Richard; Jeanne Cook-Moreau; Jacques Monteil; Benoît Funalot; Franck G Sturtz
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

2.  Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes.

Authors:  Elana J Fertig; Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Sci Rep       Date:  2015-07-15       Impact factor: 4.379

Review 3.  Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Authors:  William J Gradishar
Journal:  Cancer Manag Res       Date:  2016-07-11       Impact factor: 3.989

Review 4.  Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.

Authors:  Heba Alshaker; Hannah Thrower; Dmitri Pchejetski
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.